Last Posted: Jan 31, 2019
- A multicenter single-arm Phase II clinical trial of second-line FOLFIRI plus panitumumab after first-line treatment with FOLFOX plus panitumumab for initial RAS wild-type colorectal cancer with evaluation of circulating tumor DNA: A protocol study.
Maeda Hiromichi et al. Oncology letters 2019 Feb 17(2) 1980-1985 - A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer.
Capalbo Carlo et al. Cancers 2019 Jan 11(2) - Impact of Family History on Prognosis of Patients with Sporadic Colorectal Cancer.
Lee Soo Young et al. Annals of surgical oncology 2019 Jan - Lynch-like syndrome is as frequent as Lynch syndrome in early-onset non-familial non-polyposis colorectal cancer.
Antelo M et al. International journal of cancer 2019 Jan - The Impact of Universal Immunohistochemistry on Lynch Syndrome Diagnosis in an Australian Colorectal Cancer Cohort.
Loh Zoe et al. Internal medicine journal 2019 Jan - Ultra-selection of metastatic colorectal cancer patients using Next Generation Sequencing to improve clinical efficacy of anti-EGFR therapy.
Vidal J et al. Annals of oncology : official journal of the European Society for Medical Oncology 2019 Jan - Earlier Colorectal Cancer Screening May Be Necessary In Patients With Li-Fraumeni Syndrome.
MacFarland Suzanne P et al. Gastroenterology 2019 156(1) 273-274 - Hereditary Colorectal Cancer Syndromes.
Snyder Carrie et al. Seminars in oncology nursing 2019 Jan - Suspected Hereditary Cancer Syndromes in Young Patients: Heterogeneous Clinical and Genetic Presentation of Colorectal Cancers.
Maletzki Claudia et al. The oncologist 2019 Jan - A panel of seven-miRNA signature in plasma as potential biomarker for colorectal cancer diagnosis.
Zhang Huo et al. Gene 2019 Mar 687246-254
.png)
No hay comentarios:
Publicar un comentario